Lifitegrast: an alternative tr...
By: Vicky Liu, PharmD Candidate c/o 2018 – On July 11, 2016, lifitegrast (Xiidra®), the first lymphocyte function-associated antigen 1 (LFA-1), was approved by FDA for the treatment of the signs and symptoms of dry eye disease. The risk for patients to develop dry eye syndrome increases with age, occurring in 5% of adults ages…